Group Health Premarin-to-EstraTab switch has 83.4% conversion rate after six months.
Executive Summary
GROUP HEALTH PREMARIN-TO-ESTRATAB SWITCH HAS 83.4% SUCCESS RATE among the 16,364 Group Health enrollees previously receiving Wyeth-Ayerst's Premarin (conjugated estrogens), Group Health Cooperative of Puget Sound Medication Use Management Director William Baluch reported at the American Society of Health-System Pharmacists mid-year clinical meeting Dec. 10 in New Orleans. The health plan switched 14,601 Premarin users (89.2%) to Solvay's estrogen replacement therapy EstraTab (esterified estrogens). After six months, 13,654 patients (83.4% of the original Premarin users) continued on EstraTab therapy, while 2,710 either were never switched from Premarin or had switched back to the Wyeth drug. The switch program began in the summer of 1991.